Market Place
Sourcing Support
Oragenics, Inc. To Present At Centurion Bahamas Summit
18 Oct 2024 //
GLOBENEWSWIRE
Oragenics Updates On Concussion Drug Phase II Preparation
09 Oct 2024 //
GLOBENEWSWIRE
Oragenics Completes Key FDA-Recognized Study For ONP-002
08 Oct 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Closing of Public Offering
05 Sep 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Pricing of Public Offering
04 Sep 2024 //
GLOBENEWSWIRE
Oragenics Prepares For Phase IIa Trial In Concussed Patients
21 Aug 2024 //
GLOBENEWSWIRE
Oragenics Updates On Drug For Concussion, Non-Compliance With NYSE Listing
16 Aug 2024 //
GLOBENEWSWIRE
Oragenics Shows ONP-002 Concussion Drug Stable Across Wide Temperature Range
14 Aug 2024 //
GLOBENEWSWIRE
Oragenics` Concussion Drug Passes FDA Genotoxicity Study
12 Aug 2024 //
GLOBENEWSWIRE
Oragenics` Concussion Drug Clears FDA Cardiotoxicity Testing
08 Aug 2024 //
GLOBENEWSWIRE
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
10 Jul 2024 //
GLOBENEWSWIRE
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
27 Jun 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Closing of Public Offering
26 Jun 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Pricing of Public Offering
25 Jun 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces Proposed Public Offering
24 Jun 2024 //
GLOBENEWSWIRE
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
20 Jun 2024 //
GLOBENEWSWIRE
Oragenics Appoints William Frank Peacock MD as Chief Clinical Officer
22 May 2024 //
GLOBENEWSWIRE
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
17 May 2024 //
GLOBENEWSWIRE
Oragenics Prepares Intranasal ONP-002 For Concussion Phase 2
16 May 2024 //
GLOBENEWSWIRE
Oragenics Partners With Avance For Phase II Concussion Trial In Australia
07 May 2024 //
GLOBENEWSWIRE
Oragenics Notified Of Non-Compliance With NYSE Additional Listing Rules
19 Apr 2024 //
BUSINESSWIRE
Oragenics Appoints James Kelly MD, Chief Medical Officer
18 Mar 2024 //
BUSINESSWIRE
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
05 Mar 2024 //
BUSINESSWIRE
Oragenics Announces Closing of Public Offering
01 Mar 2024 //
BUSINESSWIRE
Oragenics Announces Proposed Public Offering
27 Feb 2024 //
BUSINESSWIRE
Oragenics Announces Pricing of Public Offering
27 Feb 2024 //
BUSINESSWIRE
Oragenics, Inc. Announces Leadership Transition
12 Feb 2024 //
BUSINESSWIRE
Oragenics Announces Expiration of Its Investment Banking Engagement Agreement
07 Feb 2024 //
BUSINESSWIRE
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
05 Feb 2024 //
BUSINESSWIRE
Oragenics Announces Termination of At-The-Market Offering Program
23 Jan 2024 //
BUSINESSWIRE
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
02 Jan 2024 //
BUSINESSWIRE
Oragenics Appointed Bruce Cassidy and John Gandolfo to Board of Directors
18 Oct 2023 //
BUSINESSWIRE
Oragenics to Acquire Odyssey’s Neurological Drug Technology Pipeline
05 Oct 2023 //
BUSINESSWIRE
Oragenics Enters into Agreement with Lantern for Replacement-Therapy Assets
29 Sep 2023 //
BUSINESSWIRE
Oragenics Project to Develop a Variant-Agnostic Protein Antigen
05 Jun 2023 //
BUSINESSWIRE
Oragenics to Participate in the World Vaccine Congress Washington
29 Mar 2023 //
BUSINESSWIRE
Oragenics Announces Positive Results in Several Lantibiotics Compounds
14 Mar 2023 //
BUSINESSWIRE
Oragenics Appoints Janet Huffman as Chief Financial Officer
08 Mar 2023 //
BUSINESSWIRE
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax
01 Mar 2023 //
BUSINESSWIRE
Oragenics, Inc. Regains Compliance with NYSE American
03 Feb 2023 //
BUSINESSWIRE
Oragenics Reports Favorable Toxicology for its COVID-19 Intranasal Vaccine
22 Dec 2022 //
BUSINESSWIRE
Oragenics, Inc. Receives NYSE American Notice
20 Dec 2022 //
BUSINESSWIRE
Oragenics, Inc. Announces New Chair
19 Dec 2022 //
BUSINESSWIRE
Oragenics to Participate in the 2022 BioFlorida Annual Conference
24 Oct 2022 //
BUSINESSWIRE
Oragenics Issues Letter to Shareholders
30 Sep 2022 //
BUSINESSWIRE
Oragenics Announces Toxicology Data for Intranasal COVID-19 Vaccine Candidate
24 Aug 2022 //
BUSINESSWIRE
Oragenics Appoints Seasoned Vaccine Exec Kimberly Murphy as President and CEO
23 Jun 2022 //
BUSINESSWIRE
Oragenics to Publish Positive Data for NT-CoV2-1 Intranasal COVID-19 Vaccine
14 Jun 2022 //
BUSINESSWIRE
Oragenics Issues Letter to Shareholders
17 May 2022 //
BUSINESSWIRE
Oragenics Extends Collaboration to Develop Vaccines against Coronaviruses
06 Apr 2022 //
BUSINESSWIRE
Oragenics Receives Audit Opinion with Going Concern Explanation
25 Mar 2022 //
BUSINESSWIRE
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on NT-CoV2-1
22 Mar 2022 //
BUSINESSWIRE
Oragenics and KBI Biopharma Enter Covid-19 Vaccine Development Partnership
10 Mar 2022 //
CONTRACTPHARMA
Oragenics Announces Positive Data on Intranasal SARS-CoV-2 Vaccine Candidate
03 Mar 2022 //
BUSINESSWIRE
Oragenics, NRC Collaborate to Develop Vaccine against the Omicron Variant
20 Dec 2021 //
BUSINESSWIRE
Oragenics Announces Positive COVID-19 Challenge Study Results
01 Dec 2021 //
BUSINESSWIRE
Oragenics Initiates COVID-19 Challenge Study
15 Sep 2021 //
BUSINESSWIRE
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice
30 Aug 2021 //
BUSINESSWIRE
Oragenics Announces Postponement of Annual Meeting of Shareholders
24 Aug 2021 //
BUSINESSWIRE
Oragenics Enters into Agreement with the National Research Council of Canada
27 Jul 2021 //
PR NEWSWIRE
